Genome-Wide Association Scan Identifies a Risk Locus for Preeclampsia on 2q14, Near the Inhibin, Beta B Gene

The Children's Hospital of Philadelphia, United States of America
PLoS ONE (Impact Factor: 3.23). 03/2012; 7(3):e33666. DOI: 10.1371/journal.pone.0033666
Source: PubMed

ABSTRACT Elucidating the genetic architecture of preeclampsia is a major goal in obstetric medicine. We have performed a genome-wide association study (GWAS) for preeclampsia in unrelated Australian individuals of Caucasian ancestry using the Illumina OmniExpress-12 BeadChip to successfully genotype 648,175 SNPs in 538 preeclampsia cases and 540 normal pregnancy controls. Two SNP associations (rs7579169, p = 3.58×10(-7), OR = 1.57; rs12711941, p = 4.26×10(-7), OR = 1.56) satisfied our genome-wide significance threshold (modified Bonferroni p<5.11×10(-7)). These SNPs reside in an intergenic region less than 15 kb downstream from the 3' terminus of the Inhibin, beta B (INHBB) gene on 2q14.2. They are in linkage disequilibrium (LD) with each other (r(2) = 0.92), but not (r(2)<0.80) with any other genotyped SNP ±250 kb. DNA re-sequencing in and around the INHBB structural gene identified an additional 25 variants. Of the 21 variants that we successfully genotyped back in the case-control cohort the most significant association observed was for a third intergenic SNP (rs7576192, p = 1.48×10(-7), OR = 1.59) in strong LD with the two significant GWAS SNPs (r(2)>0.92). We attempted to provide evidence of a putative regulatory role for these SNPs using bioinformatic analyses and found that they all reside within regions of low sequence conservation and/or low complexity, suggesting functional importance is low. We also explored the mRNA expression in decidua of genes ±500 kb of INHBB and found a nominally significant correlation between a transcript encoded by the EPB41L5 gene, ∼250 kb centromeric to INHBB, and preeclampsia (p = 0.03). We were unable to replicate the associations shown by the significant GWAS SNPs in case-control cohorts from Norway and Finland, leading us to conclude that it is more likely that these SNPs are in LD with as yet unidentified causal variant(s).

Download full-text


Available from: Lawrence J Abraham, Sep 03, 2015
  • Source
    • "These infants are commonly born preterm and/or growth restricted, and those who do not succumb to the twofold-increased risk of neonatal mortality [9] are susceptible to long-term neurological disability, as well as cardiovascular and metabolic diseases in later life [10]. The pathogenesis of preeclampsia remains incompletely understood, but is thought to involve a maternal genetic predisposition [11] which leads to defective placentation "
    [Show abstract] [Hide abstract]
    ABSTRACT: The neurological complications of preeclampsia and eclampsia are responsible for a major proportion of the morbidity and mortality arising from these conditions, for women and their infants alike. This paper outlines the evidence base for contemporary management principles pertaining to the neurological sequelae of preeclampsia, primarily from the maternal perspective, but with consideration of fetal and neonatal aspects as well. It concludes with a discussion regarding future directions in the management of this potentially lethal condition.
    Obstetrics and Gynecology International 12/2013; 2013:985606. DOI:10.1155/2013/985606
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Coagulation allelic variants associated with venous thromboembolism (VTE) have been suggested to be involved in the pathogenesis of ischemic stroke. This nationwide study aimed at determining whether VTE shares familial susceptibility with ischemic stroke. The Swedish Multigeneration Register of 0- to 75-year-old subjects was linked to the Swedish Hospital Discharge Register and the Cause of Death Register for the period 1987 to 2007. Odds ratios (ORs) for VTE and ischemic stroke were determined in 2 ways: odds of ischemic stroke in offspring whose parents had been diagnosed with VTE, and odds of VTE in offspring whose parents had been diagnosed with ischemic stroke. The analyses were repeated for siblings and spouses. Offspring of parents with VTE (n=25,929) were at increased risk for ischemic stroke (n=5595): OR, 1.10 (95% confidence interval [CI], 1.06-1.14). Siblings of probands with VTE (n=45,132) had no increased risk of ischemic stroke (n=1716): OR, 1.05 (95% CI, 1.00-1.11). Spouses of probands with VTE (n=24,106) were at increased risk for ischemic stroke (n=940): OR, 1.18 (95% CI, 1.10-1.27). The risks for VTE in relatives of probands with ischemic stroke were OR, 1.15; 95% CI, 1.10-1.21 (offspring); OR, 1.07; 95% CI, 1.02-1.12 (siblings); and OR, 1.21; 95% CI, 1.11-1.32 (spouses). VTE does not share strong familial susceptibility with ischemic stroke in the Swedish population. Moreover, familial nongenetic factors contribute to the observed weak familial associations. The present study suggests that it is unlikely that strong shared disease-causing mutations exist to a large extent in the Swedish population.
    Circulation Cardiovascular Genetics 08/2011; 4(5):484-90. DOI:10.1161/CIRCGENETICS.111.959882 · 5.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: According to the epidemiological research both maternal and fetal genes influence in predisposition to pre-eclampsia (PE). We have previously detected linkage signals in Finnish families on chromosomes 2p25, 4q32, and 9p13 using maternal phenotypes. Our aim was to perform a follow-up linkage analysis using updated maternal phenotypes and an unprecedented linkage analysis using fetal phenotypes. We performed a non-parametric linkage analysis using the same sample set and microsatellite markers as reported in the original linkage study (Laivuori et al., [1]). Markers genotyped were available from 237 individuals in 15 Finnish families including 72 affected mothers (pregnancy complicated by PE n=54, eclampsia n=1, or gestational hypertension [GHT] n=17), and 49 affected fetuses (born from a pregnancy complicated by PE n=45, or GHT n=4). MERLIN software (Abecasis et al., 2002) was used for sample and marker quality control and linkage analysis. Results from this study were compared against the original results obtained by using GENEHUNTER 2.1 software. The maximum nonparametric linkage (NPL) scores on chromosome 2 were at 21.70cM near marker D2S168 using maternal and fetal phenotypes (NPL score 3.79, p=0.00008, and NPL score 2.95, p=0.002, respectively). On chromosome 4 the highest peak was at 158.20 cM near marker D4S413 using maternal phenotypes (NPL score 3.13 p=0.0009), and at 109.60 cM near marker D4S1572 using fetal phenotypes (NPL score 2.50, p=0.006). On chromosome 9 the highest peaks using maternal phenotypes were at 38.90cM near marker D9S169 (NPL=3.76, p=0.00008), and at 120.80 cM near marker D9S1811 (NPL=2.74, p=0.003). The maximum peak on chromosome 9 using fetal phenotypes was found at 59.20cM near marker D9S175 (NPL=2.69, p=0.004). We found a suggestive linkage on chromosome 18 at 86.80cM near marker D18S64 using fetal phenotypes (NPL score of 2.51, p=0.006), but the highest peak using maternal phenotypes did not reach significance. In this follow-up study we have confirmed the linkage signals identified in the original linkage analysis using maternal phenotypes. Linkage to chromosome 2 was also supported by analysis using fetal phenotypes. Chromosome 18 may harbour a new fetal susceptibility locus for PE. Copyright © 2012. Published by Elsevier B.V.
    European journal of human genetics: EJHG 02/2013; 2(3). DOI:10.1038/ejhg.2013.6 · 4.23 Impact Factor
Show more